aff
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer2017· letter· en· New England Journal of Medicine· Medicine
2,575
citations
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.